# Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

> **NCT07686796** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 148 (estimated)

## Conditions studied

- Local Advanced Rectal Cancer
- PD-1 Inhibitor
- PCSK9 Inhibitor
- RCT
- Radiotherapy
- Capecitabine
- Oxaliplatin

## Interventions

- **RADIATION:** Short-course radiotherapy
- **DRUG:** CAPOX (oxaliplatin/capecitabine)
- **DRUG:** Sintilimab
- **DRUG:** Tafolecimab

## Key facts

- **NCT ID:** NCT07686796
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-01
- **Primary completion:** 2030-01-01
- **Final completion:** 2035-01-01
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2026-07-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686796, "Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*